TransEnterix's shares have been on a wild ride this year, driven primarily by SurgiBot's outstanding commercial opportunities in the robotic surgery market that's currently dominated by Intuitive Surgical 's da Vinci surgical system. Basically, some analysts expected SurgiBot to have the competitive juice to take a big bite out of Intuitive's overwhelming market share that consists of over 3,600 units installed worldwide. With this opportunity now off the table, though, TransEnterix's shares immediately gave back nearly all of their monstrous gains over the past three months.